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1. Introduction
The central nervous system (CNS) relays 
motor commands to skeletal muscle 
through motor neurons (MNs), special-
ized nerve cells located in the brainstem, 
and spinal cord. The degeneration of 
MNs and their synaptic connections with 
muscle underlies several paralyzing and 
often fatal neuromuscular diseases. Con-
sequently, understanding nerve–muscle 
connectivity is key to developing medical 
interventions which preserve or restore 
vital motor functions in humans.
During embryonic development in 
vertebrates, MNs emerge from ven-
tral progenitor domains in the caudal 
neural tube[1] and project axons into 
the surrounding mesenchyme.[2] Motor 
axon growth cones then navigate toward 
their specific target muscle in a series of 
binary pathway choices, guided by local 
positional cues.[3] As they approach their 
synaptic targets, the release of agrin and 
acetylcholine from motor axons induces 
a redistribution of nicotinic acetylcho-
line receptors (AChRs) on myofibres through interactions 
that involve the activation of the Lrp4/Musk/Rapsyn receptor 
complex on the postsynaptic side.[4] This leads to an align-
ment of postsynaptic AChR clusters with presynaptic sites, the 
exclusion of AChRs from areas not occupied by axonal con-
tacts, and the formation of the postsynaptic specialization at 
the neuromuscular junction (NMJ).[5] As NMJs mature, they 
stabilize and increase in size, a process that is dependent on 
neural activity and cholinergic neurotransmission between 
motor axon and myofibre.[6] The outgrowth of peripheral 
motor axons and the establishment of NMJs are crucial steps 
in connecting the CNS to muscles throughout the body and 
are essential for motor functions such as locomotion, posture, 
and breathing.
Loss of NMJ stability is an early pathological feature of 
amyotrophic lateral sclerosis (ALS), a fatal adult-onset neuro-
degenerative disease caused by the selective degeneration of 
MNs. About 15–20% of all ALS cases are familial, and some 
of the most common genetic defects associated with ALS are 
point mutations in the superoxide dismutase-1 (SOD1) gene.[7] 
Motor neurons project axons from the hindbrain and spinal cord to muscle, 
where they induce myofibre contractions through neurotransmitter release 
at neuromuscular junctions. Studies of neuromuscular junction formation 
and homeostasis have been largely confined to in vivo models. In this study, 
three powerful tools have been merged—pluripotent stem cells, optogenetics, 
and microfabrication—and an open microdevice is designed in which 
motor axons grow from a neural compartment containing embryonic stem 
cell-derived motor neurons and astrocytes through microchannels to form 
functional neuromuscular junctions with contractile myofibres in a separate 
compartment. Optogenetic entrainment of motor neurons in this reductionist 
neuromuscular circuit enhances neuromuscular junction formation more than 
twofold, mirroring the activity-dependence of synapse development in vivo. 
An established motor neuron disease model is incorporated into the system 
and it is found that coculture of motor neurons with SOD1G93A astrocytes 
results in denervation of the central compartment and diminishes myofibre 
contractions, a phenotype which is rescued by the receptor interacting serine/
threonine kinase 1 inhibitor necrostatin. This coculture system replicates 
key aspects of nerve–muscle connectivity in vivo and represents a rapid and 
scalable alternative to animal models of neuromuscular function and disease.
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The degenerative process caused by these mutations is charac-
terized by retraction of motor axons from the NMJ, an event 
observed before the onset of MN cell death or clinical symp-
toms in both the case reports of a human ALS patient and the 
SOD1G93A ALS mouse model.[8] The loss of motor innervation 
appears to be critical to the disease process, as stabilization of 
NMJs with an anti-Musk antibody in vivo promotes MN sur-
vival and extends the life span of SOD1G93A mice.[9] Cell–cell 
interactions within the CNS can impact on the peripheral 
pathology and represent a key factor in ALS. MNs exposed to 
astrocytes (ACs) expressing a mutant SOD1 gene show accel-
erated disease progression in vivo,[10] and coculture of normal 
MNs with mutant SOD1-ACs induces MN degeneration.[11] 
This process is driven by the reactive state of ALS-related ACs 
and the soluble factors they release.[12]
A key advance in modeling both normal MN biology and MN 
disease was the establishment of in vitro derivation protocols 
capable of generating large numbers (>106) of MNs from pluri-
potent stem cells (PSCs).[13] These protocols use chemical cues 
that govern normal neurogenesis in the spinal cord and emu-
late the developmental program of MN specification, allowing 
the study of transcriptional programs of MN differentiation,[14] 
cellular mechanisms of MN degeneration,[15] and local spinal 
circuit formation.[16] Nevertheless, MNs in these models lack 
their normal functional context, because they are not connected 
to myofibres through NMJs.
In vitro cocultures of primary MNs and myofibres have long 
been used to model neuromuscular circuits. An early culture 
system was established by Fischbach in the 1970s and consisted 
of spinal cord cells grown on a monolayer of myofibres.[17] 
Later formats included organotypic cocultures of spinal cord 
slices and muscle,[18] and MN/myofibre cocultures in microflu-
idic devices.[19] Adapting these cell culture techniques, several 
groups developed PSC–MN/myofibre coculture systems,[20] and 
employed optogenetics to selectively control neural activity of 
MNs and myofibre contractions.[21] These reports have pro-
vided important insights into factors influencing NMJ stability, 
but unlike in vivo muscle, NMJs and myofibres were often 
intermixed with MN cell bodies, and 2D cocultures typically 
lack a hydrogel scaffold that would stabilize myofibres during 
contractions.
Building on studies which showed that cultured myofibres 
can be stabilized by a combination of hydrogel embedding and 
attachments to artificial anchor points,[22] Kamm and co-workers 
were able to model a neuromuscular circuit in microfluidic 
devices, where optogenetic MNs were cocultured with myofi-
bres.[23] These devices however lack miniaturization, segrega-
tion of neural cell bodies and myofibres, and open access of 
cells to the medium. In this paper we address these issues and 
report the development of a PSC-based model of NMJ forma-
tion and neuromuscular disease. The device described here is 
more than tenfold smaller, easier to manufacture, uses defined 
neural cell populations, allows optogenetic entrainment of 
NMJs, and direct quantification of myofibre contractions. MNs 
and ACs were derived separately from mouse embryonic stem 
cells (ESCs) in vitro, purified, aggregated into 3D spheres and 
plated on an open tissue culture device. ESC-MNs projected 
axons through microchannels connecting the neural com-
partment with the myofibre compartment and formed NMJs 
with chick primary myofibres. This arrangement recapitulates 
the anatomical separation of the CNS and muscle in vivo. By 
using ESC-MNs that stably expressed the genetically encoded 
channelrhodopsin-2H134R (ChR2) photosensor,[24] we were able 
to selectively elicit MN activity with blue light without mechan-
ical interference. To validate our in vitro model, we sought to 
verify that it could emulate key features of neuromuscular cir-
cuits in vivo. First, we demonstrated that optogenetic entrain-
ment promoted NMJ formation of ChR2-positive MNs, with 
markedly greater synapse formation compared to inactive 
controls. Second, we showed that MNs cocultured with ALS-
related SOD1G93A-ACs initially project normally to the myofibre 
compartment, but then display loss of axonal projections and 
reduced light-depended myofibre contractions. This dete-
rioration of motor innervation resembles the early peripheral 
pathology of ALS seen in human patients and rodent models.
2. Results
2.1. Generation of Stable Cocultures of Optogenetic ESC-MNs 
and ESC-ACs
To generate a reliable source for enriched ESC-derived spinal-
type MNs[25] and ACs[26] for the neural component of the neu-
romuscular model, we first optimized traditional ESC media 
compositions, culture conditions, and differentiation protocols 
(Figure S1 and the Experimental Section of the Supporting 
Information). We also equipped the GFAP::CD14 AC reporter 
ESC clone (here referred to as WT, wild-type) with the “Glia-
derived neurotrophic factor”[27] (Gdnf)-expressing CAG::Gdnf 
transgene to improve MN survival in MN/AC cocultures. 
Gdnf-ACs were enriched by magnetic-activated cell sorting 
(MACS) (Figure 1A,B) using the CD14 cell-surface reporter 
and plated as a monolayer along with ChR2-MNs, which were 
MACS-enriched with the MN-specific Hb9::CD14-IRES-GFP 
reporter.[25] Gdnf expression in sorted Gdnf-ACs was confirmed 
by immunocytochemistry (Figure 1C) and quantitative poly-
merase chain reaction (qPCR) analysis (Table S1, Supporting 
Information). Nearly all MNs died within 7 days when cultured 
on WT-ACs in the absence of neurotrophic support. By con-
trast, MNs cocultured with Gdnf-ACs survived for 35 days in 
culture. The addition of recombinant Gdnf to cocultures with 
WT-ACs promoted MN survival to a lesser extent than coplating 
with Gdnf-ACs (Figure 1D).
ChR2[24] is the most commonly used optogenetic actuator, 
and our group has previously characterized the electrophysio-
logical properties of ESC-derived ChR2-MNs in vitro and demo-
nstrated their ability to trigger muscle contractions in vivo.[26] 
However, orange-red light offers the advantage of better tissue 
penetration and lower phototoxicity over blue light. To identify 
an optimal optogenetic actuator for our model, we compared 
the properties of MNs expressing red-activatable channelrho-
dopsin (ReaChR),[28] a light-activated channel with optimal 
excitation in orange-red spectrum (λ ≈ 590–630 nm), with 
ChR2-expressing MNs.
Purified MNs expressing ChR2 or ReaChR (Figure S2, Sup-
porting Information) were cocultured with Gdnf-ACs for up 
to 21 days, then whole-cell current-clamp recordings were 
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performed to characterize MN maturation[20a,29] and deter-
mine the suitability of optogenetic actuators. Both ChR2- and 
ReaChR-expressing MNs matured electrophysiologically 
over three weeks as expected of nonoptogenetic ESC-MNs[20a] 
(Figure S3A–G, Supporting Information). However, the relatively 
higher capacity of ChR2-MNs to fire sustained bursts of high 
frequency action potentials of larger amplitude (Figure S3H–J, 
Supporting Information), and their faster recovery to resting 
Adv. Biosys. 2019, 1800307
Figure 1. ESC-ACs differentiated from GFAP::CD14/CAG::Gdnf ESCs. A) Gdnf-AC cultures without and with anti-CD14 enrichment by MACS. Cells were 
labeled for the AC markers Gfap and Vimentin; scale bar 50 µm. B) Top: Representative flow cytometry analysis of anti-CD14-enriched ACs showing the 
percentage of ACs in differentiation cultures prior (black) and after (red) MACS. Bottom: AC enrichment was quantified in n = 7 independent experi-
ments. Lines indicate mean and SD, individual experiments are represented by points. C) Gdnf detection in WT and Gdnf-ACs. Cells were labeled for 
the AC markers Gfap and Glast, and for Gdnf; scale bar 50 µm. D) Long-term survival of motor neurons cocultured with WT-ACs in medium without 
(dashed line) or with recombinant Gdnf (solid grey line) and Gdnf-ACs (magenta line) in medium without Gdnf (n = 3, each experiment in triplicate). 
From day 7 onward all data points of ChR2-MN/WT-AC without recombinant Gdnf are significantly different from both other groups (not shown in the 
figure, p < 0.0001). Two-way ANOVA, *p < 0.05, ***p < 0.001, n.s. not significant (p > 0.05). Error bars indicate SD.
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membrane potential following cessation of light exposure 
(Figure S3K, Supporting Information), engenders their greater 
suitability for our neuromuscular model.
In summary, we have optimized differentiation protocols for 
mouse ESC-derived MNs and ACs, established long term viable 
cocultures of MN and ACs, and identified ChR2 as the more 
appropriate optogenetic actuator for MN stimulation. We next 
set out to engineer a coculture platform to model the NMJ in 
vitro.
2.2. Assembly of Neuromuscular Circuits in Compartmentalized 
Tissue Culture Devices
The dimensions of the coculture device (5 mm2) we designed 
are ≈20–60 times smaller than those of other compartmental-
ized culture systems[23,30] (≈100–300 mm2), which enabled us 
to mount an array of devices onto one plate (Figure 2) and 
perform several replicates in each culture. The device had one 
central myofibre compartment and two outer compartments 
for MN/AC aggregates, each 2 mm long and 500 µm wide; the 
compartments were linked by 500 µm long microchannels, 
10 µm in width and height. The channels allowed motor axons 
to project through while maintaining separation of MN and 
myofibre cell bodies. The presence of two outer compartments 
provided the option to compare MN/AC aggregates with two 
different genotypes that project axons onto the same myofibre 
target in one device. We opted to produce open devices, since 
it has been reported that neurons cultured in closed devices 
have a reduced survival time.[31] A silicon wafer mold was pre-
pared by standard photolithography techniques. The devices 
were then fabricated by soft lithography[32] by pouring polydi-
methylsiloxane (PDMS) over the wafer and curing it at 80 °C. 
The cured PDMS was peeled off the wafer, cut into sections of 
3 × 3 or 3 × 2 devices, and attached onto glass-bottom dishes 
by plasma bonding. The fabricated devices closely matched our 
design (Figure S4, Supporting Information). We then manu-
ally added two drops of the photopolymer NOA-73 as anchor 
points for myofibres (Figure S5, Supporting Information) to the 
bottom of the central compartment (Figure 2).
Adv. Biosys. 2019, 1800307
Figure 2. Manufacturing procedure used to generate open microdevices. PDMS was poured and spread onto a silicon wafer. After curing, the PDMS 
replica was peeled off from the silicon wafer, cut into a smaller 3 × 3 (or 2 × 3) platform format, and plasma bonded to a glass substrate. NOA-73 drops 
of ≈150–200 µm diameter were added to the central compartment in register with microchannels four and nine, and cured with UV light.
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MACS-sorted MNs and ACs were clustered into 3D aggre-
gates of 5000 cells per cell type prior to seeding in the device 
(Figure S6A, Supporting Information). This ensured that 
equal numbers of cells were plated in the outer compartments 
and prevented the spill-over of single MNs into the myofibre 
compartment. Three MN/AC aggregates per outer compart-
ment were plated in a fibrin/matrigel hydrogel to immobilize 
them during the subsequent handling of the device. The next 
day chick embryonic myoblasts were added to the bottom of 
the central compartment and embedded in a fibrin/matrigel 
hydrogel (Figure S6B, Supporting Information). Chick myofi-
bres were selected as the synaptic targets because they are 
known to form stable and functional NMJs with ESC-MNs.[20] 
The myoblasts fused and matured into a 3D sheet of striated 
myofibres (Figure 3A,B), held in place by the anchor points. 
The myofibres mostly aligned with the long axis of the central 
compartment (Figure 3C), and formed synaptic contacts with 
motor axons (Figure 3D) which morphologically resemble 
NMJs in vivo.
2.3. Synapse Formation In Vitro is Dependent on Neural Activity 
of MNs
To investigate the impact of neural activity on NMJ formation 
in vitro, we plated light-responsive ChR2-MNs and light-insen-
sitive WT-MNs, both aggregated with Gdnf-ACs, separately 
in the two outer compartments of the same device. One day 
later, myoblasts were seeded into the central compartment 
(Figure 4A). During the first few days of culture, ChR2-MNs 
and WT-MNs projected axons through the microchannels to 
contact myofibres. ChR2-MNs were entrained with blue light 
between day 5 and day 9 (1 h per day at 5 Hz, 20 ms epoch). 
During the optical entrainment, all cell types were subjected 
to the light stimulus. To determine if motor axons established 
functional connections with myofibres, we assessed the forma-
tion of synapses between optogenetically entrained ChR2-MNs 
and myofibres at day 9 of the coculture by measuring myofibre 
contraction velocity in response to neuron activation using par-
ticle image velocimetry (PIV). The basic working principles of 
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Figure 3. Morphological analysis of myofibres. A) Fused myofibres in the central compartment at day 9 were identified by Titin labeling; β3-tubulin labels 
motor axons. The outlines of the compartment boundaries and microchannels are shown as a white dotted line. Scale bar 100 µm. B) Titin staining of 
the cultured myofibres shows that they have matured and show striations. Scale bar 25 µm. C) Myofibres preferentially align with the long axis of the 
central compartment (0° angle), as determined by Fourier analysis (n = 6 z-stacks of different devices). Error bars indicate SD. D) 3D-reconstruction 
of an in vitro NMJ. The sample was stained with antibodies to the presynaptic marker Sv2, YFP, and the postsynaptic marker AChR. Scale bar 5 µm.
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PIV consist in dividing an image into small pixel blocks, the 
size of which is determined by the users. The local displace-
ment is then computed by comparing two consecutive images 
using correlation maximization methods. For each block on 
image (n), the algorithm finds the position of a block of pixels in 
image (n + 1) that resembles most the initial one within some 
boundary limits around the original position. This approach 
thus enables to measure a displacement map with a control-
lable coarse grain approximation. The displacement is repre-
sented by a field of arrows, the size of which is proportional 
to the local displacement. PIV analysis was initially established 
with cocultures containing ChR2-MNs only (Figure S7A,B, 
Videos S1 and S2, Supporting Information), and then applied 
to devices with ChR2- and WT-MNs (Figure 4B,C).
The myofibre sheet was recorded for 2 s (100 ms per 
frame) during which ChR2-MNs were activated by a 500 ms 
pulse of blue light (470 nm). Upon ChR2-MN light-driven 
stimulation, myofibres rapidly contracted and then slowly 
relaxed to a prestimulation state (Figure 4B). To test if the 
contraction was driven by synaptic transmission between 
ChR2-MN and myofibres, we restimulated the cultures in 
the presence of the competitive AChR antagonist, tubocur-
arine (Figure 4B,C), which completely blocked the myofibre 
displacement response to blue light. Likewise, the sodium 
channel inhibitor tetrodotoxin blocked myofibre contrac-
tions induced by light-stimulation of ChR2-MNs (Figure S8, 
Supporting Information).
We analyzed the innervation of myofibres in the devices 
on day 9 to evaluate the effect of MN entrainment on NMJ 
formation. We were able to detect an increase of presynaptic 
(Figure 4D,E) and postsynaptic (Figure 4F,G) structures in 
association with ChR2-MNs. While β3-tubulin+ axons from 
both ChR2- and WT-MNs extended through the microchannels 
and covered similar areas in the central myofibre compartment 
(Figure 4H,I), the number of synapses formed by ChR2-MNs 
onto myofibres was markedly higher than those formed by 
WT-MNs (Figure 4J,K).
We next addressed if enhancement of NMJ formation by 
optogenetic entrainment also increased the myofibre response. 
To this end, we loaded ChR2-MN/Gdnf-AC aggregates into both 
outer compartments and myofibres into the central compart-
ment, and either exposed the devices to blue light stimulation 
(Figure 4A), or left them unstimulated for the entire culture 
period. Entrained cultures showed increased myofibre contrac-
tions in response to light (Figure 5A), as well as increased presyn-
aptic (Figure 5B,C) and postsynaptic (Figure 5D,E) structures. In 
contrast to cocultures of WT-MNs and ChR2-MNs in the same 
device (Figure 4H,I), entrained ChR2-MNs showed increased 
motor axon outgrowth compared to inactive ones (Figure 5F,G). 
Consistent with the previous experiment (Figure 4J,K), neural 
activity promoted NMJ formation (Figure 5H,I).
Taken together, these data indicate that optogenetic stimulation 
of ESC-MNs induced contractions of the myofibre sheet in the 
central compartment, a response that depended on cholinergic 
neurotransmission. Furthermore, optogenetic entrainment of 
ESC-MNs enhanced the number of synaptic contacts formed 
onto myofibres.
2.4. Coculture of MNs with SOD1G93A-ACs Causes Denervation 
and Reduced Myofibre Contractions
The early disease stages in the SOD1G93A rodent in vivo model 
of ALS are characterized by muscle weakness due to denerva-
tion.[33] Despite this, in vitro models of ALS typically focus on 
MN survival, measuring the endpoint of the disease,[34] but not 
the preceding deterioration of muscle innervation and function. 
To determine if we could recapitulate “peripheral” ALS pheno-
types in our neuromuscular system, we exposed normal MNs 
to ACs expressing SOD1G93A. Such cocultures are an estab-
lished model for nonautonomous aspects of cellular degenera-
tion in ALS.[11]
In ESC-ACs carrying the CAG::SOD1G93A transgene, the con-
stitutive expression of human SOD1 is 1.4 times higher than 
endogenous mouse SOD1 (Table S1, Supporting Information). 
Additionally, SOD1G93A-ACs contained more Ubiquitin-posi-
tive cytoplasmatic inclusions than WT-AC controls (Figure S9, 
Supporting Information). Such inclusions are a pathological 
feature of ACs in mutant SOD1 models of ALS.[35] Since the 
SOD1G93A-ACs do not express Gdnf, which is required for 
MN survival (Figure 1D), we employed ChR2-MNs which also 
carry the CAG::Gdnf transgene.[26] We first evaluated the sur-
vival of Gdnf/ChR2-MNs in 2D cocultures with WT-ACs or 
SOD1G93A-ACs. Up to day 14 there was no significant difference 
in the survival rate of Gdnf/ChR2-MNs cocultured with either 
WT- or SOD1G93A-ACs. However, from day 21 until day 35 the 
survival rate of MNs cocultured with SOD1G93A-ACs was signif-
icantly lower compared to cocultures with WT-ACs (Figure 6B).
We aggregated Gdnf/ChR2-MNs with WT- and/or SOD1G93A-ACs 
mixed at different ratios (100/0, 90/10, 50/50, 0/100) to test if 
we could titrate the toxic effect of SOD1G93A. MN/AC aggregates 
and myoblasts were loaded into device as before (Figure 6A). 
On day 1, MNs exposed to WT- and/or SOD1G93A-ACs extended 
axons through the channels and contacted myofibres. We found 
no difference in motor axons extending into the myofibre com-
partment between MNs associated with ACs of the two geno-
types (Figure 6C; Figure S10A, Supporting Information). On 
days 5 and 6, Gdnf-/ChR2-MNs were optically entrained for 
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Figure 4. In vitro neuromuscular circuits assembled in a compartmentalized device. A) Experimental design outline. B) Myofibre contractions recorded 
in devices containing ChR2-MNs in one side and WT-MNs on the other side. Blue box represents a 500 ms light stimulation. Black and red lines 
represent cultures in medium without and with tubocurarine, respectively (n = 3 measurements with separate devices were performed in triplicate); 
error bars indicate SD. C) Maximum mean displacement during light stimulation. x-axis: individual devices. D–K) Analysis of synapse formation in 
response to neural activity: Representative confocal images and quantification of presynaptic and postsynaptic structures D,E) Sv2 and F,G) AChR. 
Presence of ChR2- and WT-motor axons was determined by total area of H,I) β3-tubulin. Colocalization between presynaptic and postsynaptic markers 
J,K) as determined by Pearson’s correlation coefficient. Measurements (number of objects, area, and colocalization) were obtained from volume ren-
dering of 40 sections (1 µm high × 126.77 µm width × 126.77 µm length) in the central compartment using Imaris software. Scale bar 50 µm. *p < 0.05, 
**p < 0.01 Mann–Whitney U (n = 7 z-stacks per condition). Lines indicate mean and SD.
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1 h per day (5 Hz, 20 ms epoch). By day 7, the 50% and 100% 
SOD1G93A-AC conditions exhibited reduced motor axon innerva-
tion of the central compartment compared to the WT-AC control 
(Figure 6D). Interestingly, there was no significant difference in 
axonal outgrowth between cultures containing only WT-ACs and 
those with 10% SOD1G93A-ACs (Figure 6D).
We measured myofibre contractions on day 7, rather than day 
9 as previously (Figure 4), because the viability of MNs exposed 
to SOD1G93A-ACs deteriorates with time (Figure 6B), and motor 
axons had formed NMJs by day 7 (Figure 6E). Myofibre con-
tractions were triggered by stimulating Gdnf/ChR2-MNs with a 
500 ms light pulse. Myofibre velocity was significantly reduced 
in all cultures containing SOD1G93A-ACs compared to those 
with 100% WT-ACs (Figure 6F; Figure S10B–E, Supporting 
Information). Thus, by using myofibre displacement as an indi-
rect measurement of synapse function, we were able to capture 
subtle denervation in the 10% SOD1G93A-ACs condition, which 
was not evident by immunocytochemistry.
We next tested if this in vitro model is in principle suitable 
to determine the activity of candidate drugs. We cocultured 
ChR2-MNs with WT- or SOD1G93A-ACs, each mixed 50:50 with 
Gdnf-ACs to provide neurotrophic support. Consistent with the 
previous experiment (Figure 6), the presence of SOD1G93A-ACs 
in aggregates resulted in axonal denervation (Figure 7A,B,E) 
and diminished myofibre contractions (Figure 7F) compared to 
WT-AC controls. Addition of the RIPK1 inhibitor Necrostatin, 
which has been previously shown to improve MN survival in 
an in vitro model of ALS,[36] completely rescued both the axon 
outgrowth (Figure 7C,D,E) and the myofibre contraction phe-
notypes in cocultures containing SOD1G93A-ACs (Figure 7F).
These observations indicate that the neuromuscular circuit 
model reported here is suitable for capturing “peripheral” 
ALS-related phenotypes of motor axon–myofibre connec-
tivity, caused by the “CNS-like” interactions of MN cell bodies 
with SOD1G93A-ACs. Furthermore, we have provided proof-
of-principle that the model can be used to test the effect of 
candidate ALS drugs.
3. Discussion
The CNS controls all motor functions through NMJs, special-
ized synapses between MNs and myofibres. An in vitro model 
of nerve–muscle communication could accelerate the discovery 
of mechanisms underlying NMJ formation and dysfunction. 
So far developing an accurate model has posed several chal-
lenges. These include ensuring defined cellular identities and 
genotypes, segregation of neural cell bodies and myofibres into 
“CNS-like” and “peripheral” areas, control over neural activity 
patterns, and stabilization of contractile myofibres. To address 
these challenges, we developed a model of neuromuscular 
circuitry that cocultures—in an open, compartmentalized 
device—neural aggregates (containing mouse ESC-derived 
MNs and ACs) with primary myofibres, connected by motor 
axons that form bonafide NMJs. As proof-of-principle that this 
model recapitulates key features of neuromuscular circuits in 
vivo, we showed that NMJ formation was enhanced by optoge-
netic entrainment of MNs, and that coculture of MNs with 
ALS-related SOD1G93A-ACs caused denervation and loss of 
neural control of myofibre contractions.
Compartmentalized tissue culture devices impose a defined 
microenvironment onto cultured neurons and have been used 
to investigate axon-specific targeting of mRNAs,[30] the response 
of neurons and their progenitors to graded chemical cues[37] and 
connectivity between different types of neurons.[38] However, in 
order to accommodate myofibres as synaptic targets of MNs in 
such devices, their design has to be modified to emulate in vivo 
muscle, as contractile myofibres will detach and collapse when 
cultured on a rigid surface.[39] First, myofibres must be embedded 
in a hydrogel scaffold, which mimics muscle extracellular matrix 
and promotes muscle maturation,[40] and second, these myofibre 
constructs then have to be attached to anchor points, which serve 
as the equivalent to tendons and keep them suspended.[22] Uzel 
et al.[23a] were the first to insert such a myofibre construct, held 
in place between flexible cantilevers, into a microfluidic device. 
Their device also includes a second, connected compartment 
for seeding embryoid bodies (EBs) which contained optogenetic 
ESC-derived MNs. The MNs formed NMJs with myofibres and 
induced light-dependent contractions, measured as cantilever 
deflection. In our study, we followed the same basic concept and 
designed a new device (Figure 8), which offers several advan-
tages and innovative features:
1) Motor axons are guided to the myofibre compartment by mi-
crochannels, which act as mechanical cues and bring more 
axons into contact with their targets.
2) The device is a simple and scalable design, made up of a one-
part PDMS construct. This allows us to perform multiple rep-
licates in each culture and lends itself toward drug screening 
assays.
3) The device is open, not microfluidic, so the compartments 
can be loaded directly and the cells are fully exposed to oxy-
gen and nutrients.[31]
4) Motor axon and myofibres are located close to the glass bot-
tom of the plate, and the hydrogel-embedded myofibre sheet 
is held in place by flat dome-shaped anchor points. This al-
lows us to directly image it and quantify contractions by PIV.
5) We use CNS-like 3D aggregates of sorted MNs and ACs, not 
EBs, and thus control cell types, cell ratios, and individual 
genotypes in the neural compartment.
Figure 5. Optogenetic entrainment enhances myofibre responses and NMJ formation of ChR2-MNs. A) Myofibre contractions recorded on day 9 in 
devices +/− light entrainment between day 5 and day 9. Blue box represents a 500 ms light stimulation. Unpaired t-test two-tailed p-value, *p < 0.05. 
Error bars indicate SD (n = 6 devices, three technical replicates per device). B–I) Analysis of synapse formation in response to neural activity: Repre-
sentative confocal images and quantification of presynaptic and postsynaptic structures B,C) Sv2 and D,E) AChR (BTX). Presence of nonentrained/
entrained motor axons was determined by total area of F,G) β3-tubulin. Colocalization between presynaptic and postsynaptic markers H,I) as deter-
mined by Pearson’s correlation coefficient. Measurements (number of objects, area, and colocalization) were obtained from volume rendering of 
40 sections (1 µm high x 126.77 µm width x 126.77 µm length) in the central compartment using Imaris software. Scale bar 50um. *p < 0.01, **p < 0.05 
Mann–Whitney U (n = 6 z-stacks per condition). Lines indicate mean and SD.
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Neuronal activity plays an important role in the develop-
ment and maturation of neuronal circuits in the brain.[41] Both 
in vivo and in vitro works have emphasized the importance of 
local (rather than global) modulation of activity, where differ-
ences in the activity between neurons drive competition for 
synaptic space.[42] Likewise, NMJ maturation has been shown 
Figure 6. Effect of SOD1G93A-ACs on neuromuscular circuits formation. A) Experimental design outline. B) Long-term viability of Gdnf/ChR2-MNs 
cocultured with WT- or SOD1G93A-ACs (n = 3 independent experiments, each performed in triplicate). MN viability decline is statistically significant 
different after day 14. Multiple t-tests, one unpaired t-test per time point, two-tailed p-value. *p < 0.05, **p < 0.01. n.s. not significant. Error bars indi-
cate SD. C) Axons present in the central compartment on day 1 quantified by the amount of YFP pixels per area. All culture conditions were equally 
permissive to initial axonal growth via microchannels towards myofibres (n = 5 images); ANOVA Kruskal–Wallis multiple comparisons test. D) At day 7, 
there was a significant decline of axons detected in the myofibre compartment in MN cocultures containing 100% or 50% SOD1G93A-ACs. There is no 
statistical difference between the MN cocultured with 100% WT-ACs and 10% SOD1G93A-ACs (100% WT-AC: n = 8; 100% SOD1G93A-ACs: n = 6; n = 7 
for the two other conditions) ANOVA Kruskal–Wallis multiple comparisons test, *p < 0.05, **p < 0.005. E) Representative confocal images of the axons 
present in the myofibre compartment of Gdnf/ChR2-MNs cocultured with 100% WT- or 100% SOD1G93A-ACs. Scale bar 50 µm. F) Myofibre contraction 
recorded in devices containing Gdnf/ChR2-MNs cocultured with WT-ACs and/or SOD1G93A-ACs. Maximum mean displacement during light stimula-
tion. We performed n = 3 measurements (100%WT-ACs, 10%SOD1G93A-ACs) or n = 4 measurements (50%SOD1G93A-ACs, 100%SOD1G93A-ACs) with 
separate devices, each of them in triplicate. Two-way ANOVA with Tukey’s multiple comparisons test, ****p < 0.0001. Lines indicate mean and SD.
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rely on the coordinated activity of MNs, as mouse mutants 
deficient in genes involved in cholinergic neurotransmission 
show defects in NMJ maturation, homeostasis, and competitive 
refinement during development.[6] We have shown that in our 
neuromuscular circuit model, the emergence of presynaptic 
and postsynaptic NMJ structures and, crucially, the alignment 
and coordination of these structures are dependent on optoge-
netic entrainment of MNs.
Figure 7. Necrostatin rescues MN dysfunction caused by SOD1G93A-ACs. A–D) Representative confocal images of the axons present in the myofibre 
compartment. ChR2-MNs were cocultured with WT- or SOD1G93A-ACs in the absence or presence of necrostatin. Scale bar: 100 µm. E) Axons are 
reduced in the myofibre compartment in MN cocultures containing SOD1G93A-ACs compared to those containing WT-ACs. This decline was rescued by 
the addition of necrostatin to the culture medium (WT-AC: n = 3; SOD1G93A-ACs: n = 4; WT-AC + necrostatin: n = 3; SOD1G93A-ACs + necrostatin: n = 3 
devices). Unpaired t-test, two-tailed p-value, *p < 0.05; **p < 0.01. F) Myofibre contraction recorded in devices containing ChR2-MNs cocultured with 
WT-ACs or SOD1G93A-ACs. Maximum mean displacement during light stimulation. We performed n = 4 measurements (WT-ACs, SOD1G93A-ACs) or 
n = 3 measurements (WT-ACs + necrostatin, SOD1G93A-ACs + necrostatin) with separate devices, each of them in triplicate. Unpaired t-test, two-tailed 
p-value, *p < 0.05. Lines indicate mean and SD.
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We were able to tightly control MN activity by loading MN/
AC aggregates, rather than EBs, into the neural compart-
ments. Whereas MNs in mixed EB cultures are spontaneously 
electrically active[20a]—likely driven by excitatory inputs 
from contaminating glutamatergic interneurons[13,16]—MNs 
in defined MN/AC cocultures show minimal non-evoked 
activity.[26] As a result, optogenetic entrainment of ChR2-pos-
itive and ChR2-negative MNs allowed us to directly compare 
active and inactive neuronal populations in the same device. 
Given this technical advantage, we anticipate that the neuro-
muscular circuit model reported here may be used to expand 
on the seminal studies that described the basic principles of 
NMJ formation and the competitive refinement of MN axons 
as they mature.
We have also demonstrated the capacity of this system for 
modeling NMJ pathophysiology. To do this we cocultured ESC-
MNs with ESC-ACs carrying an ALS-linked SOD1G93A muta-
tion. In this coculture we observed denervation of myofibres 
and reduced muscle contraction, mimicking key features 
of the disease in humans. We were able to titrate the detri-
mental effect of SOD1G93A by changing the ratio of WT- and 
SOD1G93A-ACs. The device culture format enabled us to pre-
cisely quantify the reduced contractile response triggered 
by MNs whose cell bodies are exposed to SOD1G93A-ACs, a 
phenotype which we could rescue with the candidate ALS drug 
Necrostatin.[36] These observations mirror NMJ degeneration 
in mutant SOD1 mice[8,43] albeit on a condensed time scale. 
To our knowledge, this study is the first to show an in vivo-like 
sequence of normal axon outgrowth followed by denervation 
in an in vitro model of ALS. Our observations on reduced 
myofibre contractions are similar to those made by Osaki 
et al.[23b] in a device-based coculture model of ALS with human 
induced pluripotent stem cell (iPSC)-motor neurons carrying a 
mutant TARDBP gene.
Given the amenability of cells in our model to the introduction 
of genetic probes and imaging techniques, other aspects of the 
peripheral pathology in the distal axon and NMJ, such as defec-
tive axonal transport and protein aggregation, could be explored 
with our experimental system. For example, live imaging with 
presynaptic and postsynaptic fluorescent markers would enable 
us to measure the dynamics of NMJ denervation in an ALS 
model, and not just the end point of the process. In future 
studies, a closer approximation to ALS in humans will require 
several refinements, in particular the differentiation of MNs, 
ACs, and myofibres from human patient-derived iPSCs and 
isogenic controls, longer-term cultures (>1 month) to account 
for the slow disease progression in human patients. We plan 
to incorporate 3D-myofibre constructs assembled with iPSC-
myoblasts in a fibrin-based hydrogel, similar to the ones recently 
described by Bursac and co-workers.[44] A further step toward 
more complex neuromuscular circuits would be the inclusion of 
additional cell types relevant to ALS, such as terminal Schwann 
cells present at the NMJ in vivo. The applications of this system 
are not limited to ALS, and it could be adapted to model other 
familial diseases affecting neuromuscular circuits, such as spinal 
muscular atrophy and muscular channelopathies.
Figure 8. In vitro model of a neuromuscular circuit in an open microdevice. In the scheme shown here, MNs of two different genotypes are plated 
separately into the two outer compartments, allowing for the direct comparison of NMJ formation by their motor axons (green and blue) in the central 
myofibre compartment. An example for this approach (with ChR2-positive and ChR2-negative MNs) is shown in Figure 4.
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4. Experimental Section
For details about the Experimental Section, see the Supporting Information.
Compartmentalized Device Fabrication: The coculture devices were 
fabricated by soft lithography,[32] i.e., casting PDMS on a silicon mold. 
From the cured PDMS sheet, rectangles containing six or nine devices 
were cut and attached to a glass bottom culture dish by plasma bonding. 
Then, two drops of the photopolymer NOA-73 were applied to the 
bottom of the central compartment and cured by UV exposure. Prior to 
plating of the cells, the devices were coated with Matrigel diluted 1:100 
in Dulbecco modified Eagle medium (DMEM).
Generation of Transgenic ESC Clones: Mouse ESC clones carrying 
MACS-sortable Hb9::CD14-IRES-GFP (MN) and GFAP::CD14 (AC) 
reporter transgenes, as well as the Hb9::CD14-IRES-GFP/CAG::ChR2-YFP 
and Hb9::CD14-IRES-GFP/CAG::ChR2-YFP/CAG::Gdnf subclones, 
have been described previously.[25,26] From the parental ESC clones, 
we generated stably transfected MN reporter subclones carrying the 
CAG::ReaChR-YFP transgenes, and AC reporter subclones carrying either 
CAG::Gdnf or CAG::SOD1G93A transgenes.
Cell Culture and Differentiation: Mouse ESCs were cultured and 
differentiated as described[25,26] with some modifications (see the 
Supporting Information). Differentiated neural cells were MACS-sorted 
with anti-CD14 antibody on day 5 (ESC-MNs) or day 12 (ESC-ACs) of 
culture. Pectoralis muscle was dissected from E12 chick embryos, and 
then dissociated to isolate primary chick myoblasts.
Electrophysiology: Whole cell patch clamp recordings were obtained 
from ESC-MNs stably expressing either ChR2 or ReaChR and cultured 
on a monolayer of Gdnf-expressing ESC-ACs for 7 and 21 days.
In Vitro Coculture of MNs, ACs, and Myoblasts: Aggregates of MACS-
sorted ESC-MNs and ESC-ACs (5000 each per aggregate) were plated 
into the outer chambers of the compartmentalized devices (Figure 2; 
Figure S6, Supporting Information) and then immobilized in a fibrin/
Matrigel hydrogel. The next day, 1000–2500 primary chick myoblasts 
were plated into the central compartment and embedded in a fibrin/
Matrigel hydrogel. The cocultures were cultured for four days and then 
optically entrained (1 h per day, 20 ms pulse at 5 Hz)[45] for the next five 
(Figures 4 and 5) or two (Figures 6 and 7) days. Myofibre contractions in 
response to light stimulation were recorded on day 9 (Figures 4 and 5) 
or day 7 (Figures 6 and 7).
Quantitative RT-PCR: Expression levels of Gdnf, mouse Sod1, human 
SOD1, and Gapdh were determined by qPCR (Table S1, Supporting 
Information) at the at the Genomics Centre (KCL) or the Centre for Stem 
Cells & Regenerative Medicine (KCL).
Immunocytochemistry: Immunocytochemistry of cultured cells was 
performed as described previously,[25] and images acquired with a 
confocal microscope (Zeiss LSM710 and LSM800, Nikon A1R) or an 
inverted fluorescence microscope (Olympus X73). Images were analyzed 
with ImageJ software and Bitplane Imaris 9.1.2. All antibodies used in 
this study are listed in Table S2 (Supporting Information).
Colocalization Analysis of Presynaptic and Postsynaptic Structures: NMJs 
and axons were labeled by immunohistochemistry with antibodies to 
Sv2, AChR (or BTX), and β3-tubulin, z-stacks of images were acquired 
with a Zeiss LSM 800 confocal microscope and analyzed with the 
Bitplane Imaris 9.1.2 software.
Time-Lapse Imaging: Myofibre contractions were induced by 
optogenetic stimulation at 470 nm with a CoolLED illumination system 
and recorded by brightfield time-lapse imaging with an inverted Olympus 
IX71 epifluorescence microscope. Myofibre contraction velocity was 
quantified by PIV using the PIVlab package within Matlab (Mathworks).
Statistical Analysis: Statistical analysis was carried out in GraphPad 
Prism or R. Information on statistical tests used for all experiments is 
shown in the figure legends and in Table S3 (Supporting Information).
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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